The Site Initiation Visit (SIV) is a foundational step in clinical trial start-up, bridging site preparation and trial activation. It allows sponsors and Clinical Research Associates (CRAs) to confirm site readiness, align expectations, and train the site team on study-specific procedures. A successful SIV hinges not just on documentation, but also on active participation and preparedness of the site staff. This guide outlines key sponsor expectations from site personnel during the SIV to help ensure GCP compliance and operational excellence.

Why Sponsor Expectations Matter at the SIV

For sponsors, the SIV is more than a procedural meeting—it’s an assurance checkpoint that the site:

• Understands the protocol and responsibilities
• Is equipped to handle subject safety and data integrity
• Is compliant with ICH-GCP, USFDA, CDSCO, and other regulatory guidelines
• Is ready to start recruitment without major gaps

Sponsors view site performance during the SIV as a predictor of study conduct quality. Poor engagement or lack of preparation may raise red flags.

Key Expectations from the Site Team During SIV

1. Full Team Attendance and Participation

• PI, Sub-Investigators, Study Coordinator, Pharmacist, and Lab Staff should be present
• All attendees should be attentive and contribute to discussions
• Late arrivals or absences may indicate disengagement or resource constraints

2. Thorough Understanding of the Protocol

• PI and staff should be familiar with visit schedules, assessments, and endpoints
• Must know inclusion/exclusion criteria without referring to the protocol document repeatedly
• Ability to answer sponsor queries about subject management

3. Familiarity with Informed Consent Process

• Staff should understand ICF elements, version control, and storage procedures
• PI should confirm they will personally conduct or supervise the consent process
• Knowledge of how to manage re-consents and translations if applicable

4. Document and System Preparedness

• Site should have a complete Investigator Site File (ISF)
• All required regulatory documents must be up to date and filed
• Access to systems like EDC, IWRS, and ePRO should be configured and tested

5. Staff Training and Delegation Readiness

• All staff must have current GCP training certificates
• Site Delegation Log should be filled and signed by the PI
• Training logs for protocol-specific topics must be prepared

6. Investigational Product (IP) Handling Preparedness

• Pharmacist should confirm IP storage is validated and logs are available
• IP temperature monitoring SOPs should be presented
• Unblinding and emergency procedures must be clearly understood

7. Engagement in Q&A and Clarifications

• Sponsors expect staff to ask relevant questions
• Clarifications on screening failures, AE reporting, or visit windows are welcome
• Silence or disinterest is seen as a negative indicator

Specific Roles and Their SIV Expectations

Principal Investigator (PI)

• Lead the site team and affirm readiness
• Demonstrate ownership over protocol conduct and subject safety
• Confirm delegation of tasks appropriately and maintain oversight

Study Coordinator

• Show preparedness for visit scheduling, data entry, and subject follow-up
• Be fluent with EDC procedures and CRA communication expectations
• Maintain logs, screening records, and site binders

Pharmacist

• Understand IP receipt, storage, labeling, and accountability
• Explain SOPs for temperature excursions and drug returns

Lab and Technical Staff

• Confirm availability and functioning of protocol-required equipment
• Present calibration logs and biospecimen processing readiness

Documentation Sponsors Expect to Review During SIV

• Updated CVs and GCP training certificates for all delegated staff
• Signed Confidentiality Agreements
• Signed Site Delegation of Authority Log
• Regulatory Binder with all approvals, logs, and study-specific SOPs
• Site Initiation Visit Attendance Log

Best Practices for Site Staff During the SIV

1. Review protocol and study documents beforehand
2. Ensure site infrastructure is clean, organized, and inspection-ready
3. Bring up previous challenges faced in similar trials for proactive problem-solving
4. Assign one person to take notes and document all SIV action points
5. Be transparent about limitations (e.g., staffing, equipment) and propose solutions

Common Pitfalls to Avoid

• Assuming the SIV is just a formality—sponsors take it seriously
• Lack of preparation or inability to answer basic protocol questions
• Incomplete regulatory files or missing essential documents
• Passive behavior or unclear roles among site staff

Conclusion

Meeting sponsor expectations during the Site Initiation Visit is crucial to earning confidence, securing trial activation, and setting the stage for strong study performance. Site staff should treat the SIV as a collaborative readiness exercise that showcases their commitment, preparation, and operational excellence. With active participation, clear communication, and thorough documentation, clinical trial sites can ensure a successful start to every study.